Prague Med. Rep. 2022, 123, 266-278
https://doi.org/10.14712/23362936.2022.25
Pervitin Intoxication with Two-peak Massive Myoglobinemia, Acute Kidney Injury and Marked Procalcitonin Increase Not Associated with Sepsis
References
1. 1999) Myoglobin clearance and removal during continuous venovenous hemofiltration. Intensive Care Med. 25(10), 1169–1172.
< , S. L., Leblanc, M., Thibeault, Y., Geadah, D., Cardinal, J. (https://doi.org/10.1007/s001340051031>
2. 1998) Ecstasy: A common cause of severe acute hepatotoxicity. J. Hepatol. 29(3), 394–397.
< , V., Mas, A., Bruguera, M., Salmeron, J. M., Moreno, V., Nogue, S., Rodes, J. (https://doi.org/10.1016/S0168-8278(98)80056-1>
3. 2019) Methamphetamine (N-methylamphetamine)-induced renal disease: Underevaluated cause of end-stage renal disease (ESRD). BMJ Case Rep. 12(9), e230288.
< , K. M., Pathireddy, S., Bose, S., Aeddula, N. R. (https://doi.org/10.1136/bcr-2019-230288>
4. 2009) Rhabdomyolysis and acute kidney injury. N. Engl. J. Med. 361(1), 62–72.
< , X., Poch, E., Grau, J. M. (https://doi.org/10.1056/NEJMra0801327>
5. 2011) Methamphetamine for Hitler’s Germany: 1937 to 1945. Bull. Anesth. Hist. 29(2), 21–24, 32.
< , R. J., Wright, A. J. (https://doi.org/10.1016/S1522-8649(11)50016-2>
6. 1996) Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin. Neuropharmacol. 19(2), 157–164.
< , M., Jankovic, J., Dean, J. M. (https://doi.org/10.1097/00002826-199619020-00004>
7. 2020) Successful reduction of creatine kinase and myoglobin levels in severe rhabdomyolysis using extracorporeal blood purification (CytoSorb®). Blood Purif. 49(6), 743–747.
< , O., Ince, C., van der Hoven, B., Thijsse, S., Ormskerk, P., de Geus, H. R. H. (https://doi.org/10.1159/000505899>
8. 2013) Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: Should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting? BMJ Case Rep. 2013, bcr2013010133.
, D., Shrestha, P., Adelman, M. (
9. 1984) Amphetamine-induced acute renal failure. South. Med. J. 77(2), 258–260.
< , R. J., Kapatkin, K., Verani, R., Weinman, E. J. (https://doi.org/10.1097/00007611-198402000-00035>
10. 2010) Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 12(5), 435–442.
< , B. E., Wiens, M. O., Brubacher, J. R. (https://doi.org/10.1017/S1481803500012598>
11. 2016) Multisystem toxicity after methamphetamine use. Clin. Case Rep. 4(3), 226–227.
< , A. (https://doi.org/10.1002/ccr3.487>
12. 2006) Acute toxic effects of “Ecstasy” (MDMA) and related compounds: Overview of pathophysiology and clinical management. Br. J. Anaesth. 96(6), 678–685.
< , A. P., Henry, J. A. (https://doi.org/10.1093/bja/ael078>
13. 2017) Diagnostic value of PCT and CRP for detecting serious bacterial infections in patients with fever of unknown origin: A systematic review and meta-analysis. Appl. Immunohistochem. Mol. Morphol. 25(8), e61–e69.
< , L., Shi, Q., Shi, M., Liu, R., Wang, C. (https://doi.org/10.1097/PAI.0000000000000552>
14. 2019) Methamphetamine presentations to an emergency department: Management and complications. Emerg. Med. Australas. 31(4), 593–599.
< , K. Z., Ayles, S. F., Harris, K., Finch, C. J., Page, C. B. (https://doi.org/10.1111/1742-6723.13219>
15. 2020) Methamphetamine intoxication and acute kidney injury: A prospective observational case series. Nephrology (Carlton) 25(10), 758–764.
< , K. Z., Mudge, D. W., Harris, K., Dimeski, G., Buckley, N. A. (https://doi.org/10.1111/nep.13762>
16. 2021) Strenuous exercise-induced tremendously elevated transaminases levels in a healthy adult: A diagnostic dilemma. Case Reports Hepatol. 2021, 6653266.
< , P., Neupane, A., Sapkota, S. R., Bashyal, B., Sharma, D., Chhetri, A., Chirag, K. C., Banjade, A., Sapkota, P., Bhandari, S. (https://doi.org/10.1155/2021/6653266>
17. 2021) Procalcitonin elevation induced by sympathomimetic drug overdose. Acute Med. Surg. 8(1), e687.
< , S., Kashiura, M., Moriya, T. (https://doi.org/10.1002/ams2.687>
18. 2004) Dantrolene – A review of its pharmacology, therapeutic use and new developments. Anaesthesia 59(4), 364–373.
< , T., Gerbershagen, M. U., Fiege, M., Weisshorn, R., Wappler, F. (https://doi.org/10.1111/j.1365-2044.2004.03658.x>
19. 2003) Hyperpyrexia and rhabdomyolysis after ecstasy (MDMA) intoxication. Anaesthesist 52(6), 511–515. (in German)
< , O., Ince, A., Kuhlen, R., Rossaint, R. (https://doi.org/10.1007/s00101-003-0474-2>
20. 1948) Psychological and physiological effects of intravenous pervitin. Am. J. Psychiatry 105(6), 429–434.
< , J., Rinkel, M., Greenblatt, M. (https://doi.org/10.1176/ajp.105.6.429>
21. 2020) The association between illicit drug use and the duration of renal replacement therapy in patients with acute kidney injury from severe rhabdomyolysis. Front. Med. (Lausanne) 7, 588114.
< , A. K. H., Azraai, M., Pham, J. H., Looi, W. F., Bennett, C. (https://doi.org/10.3389/fmed.2020.588114>
22. 2014) Extreme procalcitonin elevation without proven bacterial infection related to amphetamine abuse. Case Rep. Crit. Care 2014, 179313.
, A., Agoston, Z., Kesmarky, K., Hankovszky, P., Molnar, Z. (
23. 2007) Role of dantrolene in the management of the acute toxic effects of Ecstasy (MDMA). Br. J. Anaesth. 99(1), 146.
< , J., Cros, J. (https://doi.org/10.1093/bja/aem154>
24. 2022) Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®) – A case report. Clin. Case Rep. 10(1), e05272.
< , E., Rugg, C., Strohle, M., Thoma, M. (https://doi.org/10.1002/ccr3.5272>
25. 2013) Diagnosis and treatment of drug-induced hyperthermia. Am. J. Health Syst. Pharm. 70(1), 34–42.
< , M. E., Saely, S. (https://doi.org/10.2146/ajhp110543>
26. 2015) Prevalence of rhabdomyolysis in sympathomimetic toxicity: A comparison of stimulants. J. Med. Toxicol. 11(2), 195–200.
< , A. D., Padilla-Jones, A., Gerkin, R. D., Levine, M. (https://doi.org/10.1007/s13181-014-0451-y>
27. 1972) Drugs, coma, and myoglobinuria. Arch. Neurol. 26(4), 336–343.
< , A. S., Rowland, L. P., Fraser, D. W. (https://doi.org/10.1001/archneur.1972.00490100066006>
28. 2008) Muscular exercise can cause highly pathological liver function tests in healthy men. Br. J. Clin. Pharmacol. 65(2), 253–259.
< , J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkstrom, V., Ekelund, M. (https://doi.org/10.1111/j.1365-2125.2007.03001.x>
29. 1999) Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am. J. Emerg. Med. 17(7), 681–685.
< , J. R., Johnson, E. B., Stark, R. W., Derlet, R. W. (https://doi.org/10.1016/S0735-6757(99)90159-6>
30. 2020) Acute poisoning with rhabdomyolysis in the intensive care unit: Risk factors for acute kidney injury and renal replacement therapy requirement. Toxics 8(4), 79.
< , P. F., Voicu, S., Labat, L., Deye, N., Malissin, I., Laplanche, J. L., Vodovar, D., Megarbane, B. (https://doi.org/10.3390/toxics8040079>
31. 2012) Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene. Anaesthesia 67(9), 1021–1024.
< , T., Riazi, S., Kraeva, N., Steel, A. C., Hawryluck, L. A. (https://doi.org/10.1111/j.1365-2044.2012.07226.x>
32. 1982) Amphetamine-associated myoglobinuric renal failure. South. Med. J. 75(2), 237–240.
< , J., Spital, A. (https://doi.org/10.1097/00007611-198202000-00033>
33. 2021) Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit. Care 25(1), 41.
< , C., Liebchen, U., Paal, M., Irlbeck, M., Zoller, M., Schroeder, I. (https://doi.org/10.1186/s13054-021-03468-x>
34. 1951) A preliminary report on the use of d-desoxyephedrine hydrochloride in the study of psychopathology and psychotherapy. Am. J. Psychiatry 107(11), 850–855.
< , J., Goolker, P. (https://doi.org/10.1176/ajp.107.11.850>
35. 2005) Trends in substance abuse by teenagers in the Czech Republic. J. Emerg. Med. 28(1), 95–100.
< , J., Polanecky, V., Sejda, J., Studnickova, B. (https://doi.org/10.1016/j.jemermed.2004.05.010>
36. 1998) Trends in the incidence of problematic drug addicts in the Czech Republic, 1995–1996. Cent. Eur. J. Public Health 6(1), 18–24.
, J., Studnickova, B., Polanecky, V. (
37. 1988) Amphetamine-induced myoglobinuric acute renal failure. Jpn. J. Med. 27(3), 305–308.
< , Y., Shinohara, S., Matui, N., Ida, T. (https://doi.org/10.2169/internalmedicine1962.27.305>
38. 2020) Myoglobin clearance with continuous veno-venous hemodialysis using high cutoff dialyzer versus continuous veno-venous hemodiafiltration using high-flux dialyzer: A prospective randomized controlled trial. Crit. Care 24(1), 644.
< , L., de Fallois, J., Haussig, E., Kaiser, T., Mende, M., Petros, S. (https://doi.org/10.1186/s13054-020-03366-8>
39. 2017) Short-term high-dose steroid therapy in a case of rhabdomyolysis refractory to intravenous fluids. Am. J. Case Rep. 18, 1110–1113.
< , F., Salehi, M., Sattar, A., Abu-Hishmeh, M., Khan, M. (https://doi.org/10.12659/AJCR.905196>
40. Zeng, X., Zhang, L., Wu, T., Fu, P. (2014) Continuous renal replacement therapy (CRRT) for rhabdomyolysis. Cochrane Database Syst. Rev. 6, CD008566.
41. 2012) Myoglobin clearance by continuous venous-venous haemofiltration in rhabdomyolysis with acute kidney injury: a case series. Injury 43(5), 619–623.
< , L., Kang, Y., Fu, P., Cao, Y., Shi, Y., Liu, F., Hu, Z., Su, B., Tang, W., Qin, W. (https://doi.org/10.1016/j.injury.2010.08.031>
42. 2019) Undifferentiated shock and extreme elevation of procalcitonin related to kratom use. Indian J. Crit. Care Med. 23(5), 239–241.
, M., Guru, P. K., Bansal, V., Diaz-Gomez, J., Grieninger, B., Alejos, D. (